Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized placebo-controlled trial of single-dose intravenous spesolimab for acute generalized pustular psoriasis flares in Japan
jRCT2080224510Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in generalized pustular psoriasis (GPP) comparing Spesolimab single-dose IV with Placebo IV (2 arms). Started Jan 2019; status: completed.
02
Drugs
spesolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on jRCT2080224510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224510.